EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Tzu-Yi Lin, Ching-Ya Wang iD, Fang-Ying Wang iD, Eugene Yu-Chuan Kang iD, Yih-Shiou Hwang iD

Pharmaceutics · 23.03.2023 · 15 (4) · 1031

DOI: 10.3390/pharmaceutics15041031 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pharmaceutics, online erschienen am 23.03.2023. Verfasst von Tzu-Yi Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conjunctivitis is commonly reported in dupilumab users with atopic dermatitis (AD), and few studies have compared the risk of conjunctivitis among patients with different indications. This study aimed to investigate the association between dupilumab and conjunctivitis in various diseases. The protocol of this study was registered on PROSPERO (ID CRD42023396204). The electronic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was conducted for the period from their inception to January 2023. Only placebo-controlled, randomized controlled trials (RCTs) were included. The main outcome was the incidence of conjunctivitis during the study period. The subgroup analysis was performed for patients with AD and non-AD indications, which include asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. In total, 23 RCTs involving 9153 patients were included for meta-analysis. Dupilumab users exhibited significantly higher risk of conjunctivitis (risk ratio [RR], 1.89; 95% confidence interval [CI], 1.34–2.67) than placebo users. Notably, significantly increased incidence of conjunctivitis was observed in the dupilumab group relative to the placebo group among patients with AD (RR, 2.43; 95% CI, 1.84–3.12) but not among patients with non-AD indications (RR, 0.71; 95% CI, 0.43–1.13). In conclusion, only dupilumab users with AD but not those with non-AD indications reported an elevated incidence of conjunctivitis.

Schlagwörter

Stichwörter der Autor:innen

adverse eventatopic dermatitisconjunctivitisdupilumabsafety

Autor:innen und Institutionen

  • Department of Education, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan.
  • School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
  • Department of Dermatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan.
  • Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 333, Taiwan.
  • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
  • Department of Ophthalmology, Jen-Ai Hospital Dali Branch, Taichung 412, Taiwan.

ORCID-Profile: Ching-Ya Wang, Fang-Ying Wang, Eugene Yu-Chuan Kang, Yih-Shiou Hwang

Zitieren

APA

Lin, T. Y., Wang, C. Y., Wang, F. Y., Kang, E. Y., & Hwang, Y. S. (2023). Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceutics, 15(4), 1031. https://doi.org/10.3390/pharmaceutics15041031

Vancouver

Lin TY, Wang CY, Wang FY, Kang EY, Hwang YS. Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceutics. 2023;15(4):1031. doi:10.3390/pharmaceutics15041031

BibTeX
@article{Lin2023,
  author = {Lin, Tzu-Yi and Wang, Ching-Ya and Wang, Fang-Ying and Kang, Eugene Yu-Chuan and Hwang, Yih-Shiou},
  title = {Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {4},
  pages = {1031},
  doi = {10.3390/pharmaceutics15041031}
}
Kostenlos starten →